Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH
Oral presentation shares head-to-head results for investigational combination pozelimab plus cemdisiran vs. ravulizumab in paroxysmal nocturnal hemoglobinuria Initial results for odronextamab in first ...
Inovio Pharmaceuticals (INO) Q3 2024 Earnings Call Transcript
Inovio Pharmaceuticals (NASDAQ: INO) Q3 2024 Earnings Call Nov 14, 2024, 4:30 p.m. ET ...
Ibotta price target lowered to $85 from $111 at JMP Securities
JMP Securities lowered the firm’s price target on Ibotta (IBTA) to $85 from $111 and keeps an Outperform rating on the shares. Ibotta ...